Combination therapy for metastatic renal cell carcinoma
- 1 March 2016
- journal article
- editorial
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (5) , 100
Abstract
Current therapy for metastatic clear cell renal cell carcinoma (RCC) consists of the serial administration of single agents. Combinations of VEGF and mTOR inhibitors have been disappointing in previous randomized trials. However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. Moreover, the emergence of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors has spawned the investigation of combinations of these agents with VEGF inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors. These ongoing phase III trials in conjunction with the development of predictive biomarkers and agents inhibiting novel therapeutic targets may provide much needed advances in this still largely incurable disease.Keywords
This publication has 17 references indexed in Scilit:
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2015
- A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancerEuropean Journal of Cancer, 2014
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT TrialJournal of Clinical Oncology, 2014
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinomaExpert Opinion on Investigational Drugs, 2013
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Cancer Chemotherapy and Pharmacology, 2013
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaCancer, 2011
- New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and ResistanceClinical Cancer Research, 2010
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell CarcinomaClinical Genitourinary Cancer, 2009
- E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionInternational Journal of Cancer, 2007